-
What are the new cancer treatments approved by the NHS?
The NHS has approved two innovative cancer treatments: belantamab mafodotin, which is aimed at treating multiple myeloma, and histotripsy, a non-invasive treatment for liver cancer. These therapies are expected to significantly improve patient outcomes.
-
How do belantamab mafodotin and histotripsy work?
Belantamab mafodotin works by targeting cancer cells in multiple myeloma, helping to extend progression-free survival for patients. Histotripsy, on the other hand, uses ultrasound technology to non-invasively destroy liver tumors, offering a promising alternative to traditional surgical methods.
-
What are the expected outcomes for patients using these treatments?
Patients using belantamab mafodotin can expect an extension in their progression-free survival, potentially keeping cancer at bay for years. Histotripsy has shown promising results in the US, with survival rates comparable to existing treatments, indicating a strong potential for success in the UK.
-
Are there any side effects or risks associated with these new therapies?
As with any cancer treatment, there may be side effects associated with belantamab mafodotin, including potential impacts on vision and immune response. Histotripsy is considered less invasive, but patients should still discuss any risks with their healthcare provider.
-
How quickly will these treatments be available to patients?
The NHS is committed to expediting access to these innovative treatments. Histotripsy is set to debut in the NHS this summer, while belantamab mafodotin is already available for eligible patients, ensuring timely access to these life-changing therapies.
-
What do experts say about these new cancer treatments?
Experts, including NHS England's Prof Peter Johnson, have described belantamab mafodotin as a 'life-changing' treatment for multiple myeloma. Health Secretary Wes Streeting has emphasized the government's commitment to innovative healthcare solutions, highlighting the potential of histotripsy to revolutionize liver cancer treatment.